AllPennyStocks.com BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation

BioCryst raised its full-year 2026 total revenue outlook to $690 million to $715 million, up from its previous estimates of $635 million to $660 million.

Other Penny Stock Movers

When Design Thinking Meets the AI Canvas
Peru Silver Restart Jumps 15% After First Concentrate Yields 29k oz Ag
PNG Explorer Rallies 18% as Drill Bit Hits High-Grade Gold Target
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top